Antares Pharma, Inc. announced that the company reaffirmed full-year 2021 revenue guidance in the range of $175 million to $200 million, which represents a 17% to 34% year-over-year growth rate and assumes no significant disruptions to supply or operations due to the ongoing COVID-19 pandemic and a range of revenue scenarios for the potential approval and launch of generic Forteo by company partner Teva in the U.S.